Purchase this article with an account.
Yew Chong Yap, Thomas Papathomas, Kamal Ahmed; Results of Intravitreal Dexamethasone Implant 0.7mg (Ozurdex) in non-infectious posterior uveitis. Invest. Ophthalmol. Vis. Sci. 2013;54(15):262.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To evaluate the safety and efficacy of Ozurdex implant in patients with posterior uveitis with CMO.
Methods: Retrospective analysis of patients reports with CMO secondary to uveitis treated with Ozurdex. Data included type of posterior uveitis, any systemic immunosuppressive therapy, Best Corrected Visual Acuity (BCVA), Central Macular Thickness (CMT) on OCT and signs of intraocular inflammation at baseline and then at 2 weeks postoperatively and monthly thereafter. Follow-up is up to 10 months. Any per-operative and post-operative complications were recorded.
Results: Six eyes of 4 patients with CMO due to uveitis treated with Ozurdex implant. Diagnosis included idiopathic panuveitis, Birdshot chorioretinopathy, idiopathic intermediate uveitis and inflammation confirmed by Fluorescein Angiography. At baseline mean logMAR BCVA was 60 letters and mean CMT 566μ. At 2 weeks postoperatively mean logMAR BCVA improved to 70 letters and mean CMT to 303μ. All eyes showed clinical evidence of decreased inflammation. The duration of effect of the implant was 5 to 6 months and retreatment was required in 2 eyes. Two patients required antiglaucoma therapy for increased intraocular pressures. No other adverse effects were recorded.
Conclusions: In patients with non-infectious posterior uveitis Ozurdex implant can be a safe and effective treatment option for controlling intraocular inflammation.
This PDF is available to Subscribers Only